Thangarasu Mathisekaran, Prakash J Sanjay, Bafna Sandeep, Aarthy P, Govindaswamy Thirumalai Ganesan, Venugopal Balaji, Sivaraman Ananthakrishnan, Jain Nitesh, Balakrishnan Arunkumar, Raghavan Deepak, Venkatraman Murali, Chandranathan M, Paul Rajesh, Selvaraj Nivash, Ramakrishnan Balasubramaniam, Ragavan Narasimhan
Department of Genitourinary Surgery, Apollo Main Hospital, Chennai, Tamil Nadu, India.
Department of Vascular Surgery, Apollo Main Hospital, Chennai, Tamil Nadu, India.
Urol Ann. 2022 Jul-Sep;14(3):273-278. doi: 10.4103/UA.UA_169_20. Epub 2022 Jul 18.
The objective of the study is to describe the perioperative outcomes, disease-specific, and overall survival status in patients diagnosed with renal cell carcinoma with inferior vena cava (IVC) tumor thrombus.
We did a retrospective analysis of all patients who underwent radical nephrectomy along with IVC thrombectomy from the year 2013 to 2020. Mayo's classification was used to stratify the level of IVC thrombus. Demographic, perioperative, histopathology data, complications, and survival status were analyzed.
Total number of patients included in the study was 39, (Male: Female = 84.6%: 15.4%). Median age of patients was 58 (interquartile range [IQR] 50-63) years. Median size of renal tumor (in cms) was 9.5 (IQR 7.5-12), 8 (IQR 7-11.5), 8.5 (IQR 7-11.75), and 11 (IQR 9.5-11) ( = 0.998) in level 1,2,3, and 4 tumors, respectively. Clear cell variant was seen in 32 patients (82%) with R0 resection in 17 patients. Twelve patients (30.7%) had systemic metastasis on presentation. The overall mean survival time was 66.4 months with 95% confidence interval (CI) (52.4-80.5 months). Mean recurrence-free survival is 76 months with (63-90) CI of 95%. Mean survival in patients who presented with metastasis is 47 months with 95% CI (52.4-80.5). Perioperative mortality rate was 5.12% in this study.
The tumor size does not have an influence on the progression of tumor thrombus into IVC. Significant difference in survival was observed between different levels of thrombus with high mortality in level four tumors.
本研究的目的是描述诊断为伴有下腔静脉(IVC)肿瘤血栓的肾细胞癌患者的围手术期结局、疾病特异性及总体生存状况。
我们对2013年至2020年期间接受根治性肾切除术及IVC血栓切除术的所有患者进行了回顾性分析。采用梅奥分类法对IVC血栓水平进行分层。分析了人口统计学、围手术期、组织病理学数据、并发症及生存状况。
纳入研究的患者总数为39例(男性:女性 = 84.6%:15.4%)。患者的中位年龄为58岁(四分位间距[IQR] 50 - 63岁)。1、2、3和4级肿瘤的肾肿瘤中位大小(厘米)分别为9.5(IQR 7.5 - 12)、8(IQR 7 - 11.5)、8.5(IQR 7 - 11.75)和11(IQR 9.5 - 11)( = 0.998)。32例患者(82%)为透明细胞变异型,17例患者实现R0切除。12例患者(30.7%)初诊时已有全身转移。总体平均生存时间为66.4个月,95%置信区间(CI)为(52.4 - 80.5个月)。平均无复发生存期为76个月,95% CI为(63 - 90)。初诊时伴有转移的患者平均生存时间为47个月,95% CI为(52.4 - 80.5)。本研究中的围手术期死亡率为5.12%。
肿瘤大小对肿瘤血栓向IVC的进展没有影响。不同血栓水平之间观察到生存存在显著差异,4级肿瘤死亡率高。